New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
05:55 EDTVSTM, VSTM, ONCY, ONCY, RIGL, RIGL, CELG, CELG, OXBT, OXBT, GALE, GALE, GTXI, GTXI, AFFY, AFFYBiotech Industry Organization to host a conference
15th Annual BIO CEO & Investor Conference is being held in New York on February 11-12.
News For CELG;OXBT;GALE;GTXI;AFFY;VSTM;ONCY;RIGL From The Last 14 Days
Check below for free stories on CELG;OXBT;GALE;GTXI;AFFY;VSTM;ONCY;RIGL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
08:34 EDTCELGPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
April 15, 2014
08:56 EDTGTXIGTx Chief Scientific Officer James Dalton resigns
GTx disclosed in a regulatory filing that James Dalton, Vice President, Chief Scientific Officer, notified the company of his decision to resign from his employment with GTx. Dalton is leaving GTx to become Dean of the University of Michigan College of Pharmacy. GTx currently expects to engage Dalton as a consultant to the company following his employment termination.
April 14, 2014
17:26 EDTGALEGalena files to sell 6M shares of common stock for holders
Subscribe for More Information
06:49 EDTONCYOncolytics Biotech reports evaluation of clinical study with REOLYSIN
Oncolytics Biotech announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. Researchers examined REOLYSIN in panels of both normal and malignant liver cells and administered either REOLYSIN or saline to SCID mice with HCV-positive HCC xenografts. The aims of the study were to assess interferon secretion in normal and malignant liver cells in response to reovirus infection; the effects of reovirus infection in normal and malignant liver cells on HBV and HCV proteins; and the anti-viral and anti-cancer effects of reovirus in vivo. Based on these results, the investigators are evaluating the conduct of a translation clinical study.
06:47 EDTONCYOncolytics Biotech collaborators present preclinical research on liver cancer
Oncolytics Biotech announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. Researchers examined Reolysin in panels of both normal and malignant liver cells and administered either Reolysin or saline to SCID mice with HCV-positive HCC xenografts. The aims of the study were to assess interferon secretion in normal and malignant liver cells in response to reovirus infection; the effects of reovirus infection in normal and malignant liver cells on HBV and HCV proteins; and the anti-viral and anti-cancer effects of reovirus in vivo. The study results showed that reovirus infection of primary human liver cells and HCC lines induced a robust type I interferon response; that reovirus-conditioned media from both primary human liver cells and JHH1 cells potently inhibits HCV and HBV in vitro with these effects abrogated by the blockade of the type I interferon receptor and soluble interferon beta; and that reovirus inhibits HCC xenograft growth and HCV replication in vivo. The researchers concluded that the results described a novel dual anti-viral and anti-cancer mechanism for reovirus in HBV/HCV-positive HCC and that reovirus treatment of patients with HBV/HCV positive HCC will likely lead to the suppression, rather than exacerbation, of the underlying oncogenic viral infection. Based on these results, the investigators are evaluating the conduct of a translation clinical study.
06:33 EDTONCYOncolytics Biotech collaborators present head, neck cancer biomarker poster
Subscribe for More Information
April 11, 2014
09:03 EDTCELGCelgene shares can unlock big value, says RBC Capital
Subscribe for More Information
April 10, 2014
12:12 EDTVSTMVerastem management to meet with Roth Capital
Subscribe for More Information
10:05 EDTCELGCelgene CEO Hugin says 'excited' about guidance for the year
Subscribe for More Information
08:10 EDTCELGCelgene likely to prevail in patent case, says Stifel
Subscribe for More Information
07:33 EDTCELGCelgene antibody could open door for new area of focus, says Wells Fargo
Wells Fargo believes that Celgene is developing an anti-CD47 antibody that could enable the company to enter the immune-oncology space and pivot into biologics. The firm views the stock as undervalued, and believes that Celgene has many viable opportunities that could enable the stock to rise over the long-term. The firm keeps an Outperform rating on the shares and identifies it as a top pick.
April 9, 2014
12:12 EDTCELGMarkman documents appear to favor Celgene, The Street says
Public documents for the pre-trial Markman hearing appear to favor Celgene over Natco, the generic drugmaker challenging some of Celgene's Revlimid patents, The Street's Adam Feuerstein reports. Shares of Celgene are up 5% to $145.33 in mid-day trading. Reference Link
07:01 EDTVSTMVerastem presents data on cancer stem cell-targeting agents at AACR
Subscribe for More Information
April 8, 2014
09:00 EDTONCYOncolytics Biotech rises 12.4%
Subscribe for More Information
06:38 EDTONCYOncolytics Biotech reports tumor stabilization or shrinkage in REOLYSIN study
Oncolytics Biotech announced additional data from the Company's randomized, double-blinded clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-na´ve head and neck cancers, or REO 018. Highlights include: 118 patients had loco-regional head and neck disease, with or without distal metastases An intent-to-treat analysis of the overall survival, or OS, of the 118 patients with loco-regional disease was performed on all patients to the median PFS in each arm, censoring any patients who received post-discontinuation therapy at the date at which they commenced the first of these therapies. This analysis demonstrated a statistically significant improvement in OS for the test arm versus the control arm; and the 118 patients with loco-regional head and neck disease, with or without distal metastases, were evaluated for percentage magnitude of tumour shrinkage at the first post-treatment scan. The test arm showed a statistical trend towards better tumour stabilization or shrinkage over the control arm. There were 47 patients with distal metastases alone. At the time of the analysis, eight of the 47 patients were still alive. The test arm patients in this group maintained a PFS benefit over control arm patients for five cycles of therapy. There are too few patients to power a statistical analysis of the PFS and OS of this patient group; and the 47 patients with distal metastases alone were evaluated for percentage magnitude of tumour shrinkage at the first post-treatment scan (performed at approximately six weeks). The test arm demonstrated statistically significantly better tumour stabilization or shrinkage than the control arm.
06:37 EDTONCYOncolytics Biotech to host conference call
Conference call to discuss additional data analysis from the Company's REO 018 trial in head and neck cancers will be held on April 8 at 7:45 am. Webcast Link
06:35 EDTONCYOncolytics Biotech announces additional data from REO 018 study of Reolysin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use